bupropion and Dysthymic Disorder studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Dysthymic Disorder: Chronically depressed mood that occurs for most of the day more days than not for at least 2 years. The required minimum duration in children to make this diagnosis is 1 year. During periods of depressed mood, at least 2 of the following additional symptoms are present: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration or difficulty making decisions, and feelings of hopelessness. (DSM-IV)

Research Excerpts

Excerpt	Relevance	Reference
"Many studies of antidepressants in the treatment of dysthymic disorder (DD) have been conducted, but none has included bupropion sustained-release (SR)."	9.09	Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study. ( Batchelder, S; Fedak, M; Hellerstein, DJ; Kreditor, D, 2001)
"Relatively treatment-naive depressed outpatients (with DSM-IV diagnoses of major depressive disorder, dysthymic disorder, or depression not otherwise specified) were initially treated with a combination of escitalopram (ESC) plus bupropion (BUP), using rapid dose escalation to ESC 40 mg/day plus BUP 400 to 450 mg/day by study day 15 in an open-label, 8-week study."	5.14	Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? ( Deliyannides, RA; McGrath, PJ; Quitkin, FM; Stewart, JW, 2009)
"Many studies of antidepressants in the treatment of dysthymic disorder (DD) have been conducted, but none has included bupropion sustained-release (SR)."	5.09	Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study. ( Batchelder, S; Fedak, M; Hellerstein, DJ; Kreditor, D, 2001)
"With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy."	1.30	Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. ( Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997)
"Major depression and dysthymia are common and often disabling disorders in late life."	1.30	Diagnosis and treatment of depression in late life. ( Downs, NS; Zisook, S, 1998)

Research

Studies (7)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Change From Baseline in the Dysphoric Apathy/Retardation Sub-factor (MDAR) of Montgomery-Asberg Depression Rating Scale (MADRS) at 4 Weeks.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (42.86)	18.2507
2000's	2 (28.57)	29.6817
2010's	1 (14.29)	24.3611
2020's	1 (14.29)	2.80

Authors	Studies
Uvais, NA	1
Basheer, S	1
Giasson-Gariépy, K	1
Jutras-Aswad, D	1
Stewart, JW	1
McGrath, PJ	1
Deliyannides, RA	1
Quitkin, FM	1
Bodkin, JA	1
Lasser, RA	1
Wines, JD	1
Gardner, DM	1
Baldessarini, RJ	1
Zisook, S	1
Downs, NS	1
Tilton, P	1
Hellerstein, DJ	1
Batchelder, S	1
Kreditor, D	1
Fedak, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication.[NCT00296712]	Phase 4	55 participants (Actual)	Interventional	2005-02-28	Completed
Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979]	Phase 4	35 participants (Actual)	Interventional	2010-09-30	Completed
Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL[NCT00225251]	Phase 4	18 participants (Actual)	Interventional	2004-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment

Beck Depression Inventory (BDI)

Intervention	scores on a scale (Mean)
	Baseline Mean MDAR score	Week 4 Mean MDAR score	Change from BL in mean MDAR score
Lisdexamfetamine Dimesylate (Vyvanse)	13.46	6.36	-7.08
Placebo Adjunct	12.57	9.08	-3.49

21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression. (NCT00225251)
Timeframe: 10 weeks

Clinical Global Improvement (CGI)

Intervention	units on a scale (Mean)
Bupropion XL	8
Placebo	12.3

A global assessment of patient improvement, ranging from 1 (very much improved) to 7 (very much worse) (NCT00225251)
Timeframe: 10 weeks

Cornell Dysthymia Rating Scale (CDRS)

Intervention	units on a scale (Mean)
Bupropion XL	2.8
Placebo	2.43

A 24 item scale assessing symptoms of chronic depression. Scores from 0 to 96 with higher score indicating worse depression (NCT00225251)
Timeframe: 10 weeks

Global Assessment of Functioning Scale (GAFS)

Intervention	units on a scale (Mean)
Bupropion XL	26.4
Placebo	24

A clinician rated assessment of patient's overall functioning, ranging from 0 (severely impaired) to 100 (excellent functioning) (NCT00225251)
Timeframe: 10 weeks

Hamilton Depression Rating Scale, 24 Items (HDRS)

Intervention	units on a scale (Mean)
Bupropion XL	64
Placebo	67

"Widely used depression rating scale, with higher scores reflecting greater level of depression. Assesses suicidality which is a safety issue.~This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (>50% decrease) Remission (score<=7)" (NCT00225251)
Timeframe: 10 weeks

Article	Year
Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? Journal of psychiatric practice, 2009, Volume: 15, Issue:5 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder; Depress	2009
Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study. Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Brief Psychiatric Rating Scale; Bupropion; Chi-Squa	2001

Article	Year
Bupropion-Induced Spontaneous Ejaculations. The primary care companion for CNS disorders, 2020, 01-02, Volume: 22, Issue:1 Topics: Adult; Antidepressive Agents; Bupropion; Dysthymic Disorder; Ejaculation; Humans; Male	2020
A case of hypomania during nicotine cessation treatment with bupropion. Addiction science & clinical practice, 2013, Dec-21, Volume: 8 Topics: Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Dysthymic Disorder; Hum	2013
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. The Journal of clinical psychiatry, 1997, Volume: 58, Issue:4 Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Anxiety Disorders; Bupropion; Depressive Disorder; Dr	1997
Diagnosis and treatment of depression in late life. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 4 Topics: Adult; Age Factors; Aged; Antidepressive Agents; Bupropion; Cognition Disorders; Combined Modality T	1998
Bupropion and guanfacine. Journal of the American Academy of Child and Adolescent Psychiatry, 1998, Volume: 37, Issue:7 Topics: Adrenergic alpha-Agonists; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with	1998

bupropion and Dysthymic Disorder